Changing trends of research and treatment in infant neuroblastoma

@article{Friedman2007ChangingTO,
  title={Changing trends of research and treatment in infant neuroblastoma},
  author={G. Friedman and R. Castleberry},
  journal={Pediatric Blood \& Cancer},
  year={2007},
  volume={49}
}
Neuroblastoma is the most common malignancy in infants and 40% of neuroblastomas are diagnosed in the first year of life. While generally neuroblastoma behaves less aggressively in this age group, tumors that have adverse biologic characteristics do not differ in their behavior from counterparts in older children. Clinical and biologic behavior of neuroblastoma in children up to 460 days of age is similar to that in children less than 1 year of age. Thus the categorization of children up to 18… Expand
Neuroblastoma in Iraq-KRG-Sulaimani
Demographic features of neuroblastoma in Iraq-Kurdistan Region- Sulaimani
Neuroblastoma
Pediatric Orbital Tumors
The Role of Ciliary Neurotrophic Factor and TRKB Signaling in Neuroblastoma
Herpes simplex virus oncolytic therapy for pediatric malignancies.
Role of the lineage gene Phox2B in neuroblastoma development.
...
1
2
3
...

References

SHOWING 1-10 OF 44 REFERENCES
Biology and treatment of neuroblastoma.
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
  • M. Schmidt, J. Lukens, +7 authors K. Matthay
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
Features and outcome of neuroblastoma detected before birth.
Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
  • M. L. Schmidt, A. Lal, +5 authors K. Matthay
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
  • R. George, W. London, +6 authors A. Look
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
...
1
2
3
4
5
...